Clinical Trial Update: A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron OCAS (Oral Controlled Absorption System) in Pediatric Subjects With Neurogenic Detrusor Overactivity or Overactive Bladder [Phase 1]

View source ↗

Summary

Phase 1 study assessing pharmacokinetics, safety and tolerability of Mirabegron OCAS in pediatric patients with Neurogenic Detrusor Overactivity or Overactive B…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neurogenic Detrusor Overactivity
• Overactive Bladder

Drugs mentioned

• Mirabegron OCAS (mirabegron)

Snippet

Sponsor: Astellas Pharma Inc | Conditions: Neurogenic Detrusor Overactivity, Overactive Bladder | Phase 1 | Status: COMPLETED